Antibodies

04 Jun 2018 Opdivo Plus Chemotherapy Showed Improved Progression-Free Survival Versus Chemotherapy in First-Line Lung Cancer Patients with PD-L1
04 Jun 2018 Immunomedics Reveals Promising Data for Sacituzumab Govitecan in Patients Heavily Pretreated for Metastatic Estrogen Receptor-Positive Breast Cancer
04 Jun 2018 Clovis Oncology and Immunomedics Announce Planned Clinical Collaboration to Study Combination Therapies in Metastatic Triple-Negative Breast and Urothelial Cancers
04 Jun 2018 FibroGen Presents Clinical Results of Pamrevlumab Treatment in Patients with Locally Advanced Unresectable Pancreatic Cancer at ASCO 2018 Annual Meeting
04 Jun 2018 INNATE PHARMA : Data from Phase I of monalizumab and durvalumab in MSS-CRC at ASCO 2018
03 Jun 2018 Five Prime Therapeutics Presents Bemarituzumab Trial-in-Progress Poster at the 2018 ASCO Annual Meeting
03 Jun 2018 Forty Seven, Inc. Announces Proof-of-Concept Data from Two Clinical Trials of 5F9 In Patients with Advanced Solid Tumors and Non-Hodgkin's Lymphoma
03 Jun 2018 Astellas and Seattle Genetics Present at ASCO 2018 on Enfortumab Vedotin in Patients with Locally Advanced or Metastatic Urothelial Cancer Previously Treated with Checkpoint Inhibitor Therapy
03 Jun 2018 Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival in First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer in Phase 3 KEYNOTE-407 Study
03 Jun 2018 KEYTRUDA® (pembrolizumab) Monotherapy Significantly Improved Overall Survival in KEYNOTE-042 Study as First-Line Treatment for Locally Advanced or Metastatic NSCLC Patients Whose Tumors Expressed PD-L1 (TPS ≥1%)
03 Jun 2018 Merck’s KEYTRUDA® (pembrolizumab) Showed Overall Response Rate of Nearly 40 Percent as First-Line Therapy in Patients with Advanced Clear Cell Renal Cell Carcinoma (RCC) in Phase 2 KEYNOTE-427 Study
03 Jun 2018 Celldex Presents Promising Data from Phase 1/2 Study of Varlilumab and Opdivo® at 2018 ASCO Annual Meeting
03 Jun 2018 Preliminary Data for NKTR-214 in Combination with Opdivo (nivolumab) for Patients with Stage IV Metastatic Melanoma, Renal Cell Carcinoma, and Urothelial Cancers Presented at ASCO 2018
03 Jun 2018 Jounce Therapeutics Presents Preliminary Efficacy Data from Ongoing Phase 1/2 ICONIC Trial of JTX-2011 in Patients with Advanced Cancers
03 Jun 2018 Moxetumomab pasudotox pivotal data in patients with previously-treated hairy cell leukemia presented at the 2018 ASCO Meeting
03 Jun 2018 European Commission approves Roche’s Perjeta for post-surgery treatment of HER2-positive early breast cancer at high risk of recurrence
02 Jun 2018 G1 Therapeutics Presents Phase 1b Data on G1T38 in Combination with Faslodex for Treatment of Breast Cancer at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
02 Jun 2018 Phase III IMpower131 Study Showed Genentech’s TECENTRIQ (Atezolizumab) Plus Chemotherapy (Carboplatin And ABRAXANE) Reduced the Risk of Disease Worsening or Death for People With Advanced Squamous Non-Small Cell Lung Cancer
02 Jun 2018 Opdivo (nivolumab) Plus Low-Dose (1mg/kg) Yervoy (ipilimumab) Provided Significant and Sustained Health-Related Quality of Life Improvements in Intermediate- and Poor-Risk Patients with Advanced Renal Cell Carcinoma in CheckMate -214 Study
02 Jun 2018 Clinical Data for Zymeworks’ Novel Bispecific Antibody, ZW25, Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
02 Jun 2018 U.S. Food and Drug Administration Lifts Partial Clinical Hold on Opdivo (nivolumab)-based Combination Study in Multiple Myeloma
01 Jun 2018 Pfizer Receives Positive CHMP Opinion for Oncology Biosimilar, TRAZIMERA™ (trastuzumab)
01 Jun 2018 Menarini Ricerche to Present the Study Design of CD205-Shuttle, a First-in-human Trial of MEN1309/OBT076, at the ASCO Annual Meeting 2018
01 Jun 2018 Daiichi Sankyo Presents Preliminary Phase 1 Data for Antibody Drug Conjugate U3-1402 in Patients with HER3-Expressing Breast Cancer at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
01 Jun 2018 Novartis receives positive CHMP opinion for Aimovig® (erenumab) for the prevention of migraine

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up
Top